Risk, prostate cancer, and being 70 to 80 years of age

So a relatively new article in Reviews in Urology caught your Sitemaster’s eye this morning — and worried him because it seemed to be communicating a conclusion of questionable accuracy, which we will explore below. And if we have misinterpreted the data provide in the paper, we are more than willing to be corrected. … READ MORE …

What’s hot at the AUA annual meeting (Sunday morning)?

So lots of posters and and presentations this morning, but not a lot of actionable information for patients (as far a we could tell). Among the more interesting papers were the following: … READ MORE …

Prostasomes — another possible marker for prostate cancer aggression?

A story in Science Daily, based on new article in the Proceedings of the National Academy of Sciences (PNAS) , has suggested that blood levels of “prostasomes” may be a more accurate marker for prostate cancer risk that PSA levels in blood. … READ MORE …

Genetic translocations and the risk for more aggressive forms of prostate cancer

A research group at Memorial Sloan-Kettering Cancer Center has published data indicating that translocation and/or deletion of the  TMPRSS2-ERG fusion gene  — which occurs in about 50 percent of the cases of clinically localized prostate cancer — is not, in fact, a prognostic indicator of risk for a more aggressive type of disease. … READ MORE …

The prognostic implications of perineural invasion at the time of surgery

A recently published Italian study has reported on whether perineural invasion (PNI) has prognostic value in patients undergoing radical prostatectomy for organ-confined prostate cancer, and on its possible correlation with other recognized prognostic factors. … READ MORE …

Brachytherapy outcomes for Gleason 7 patients by primary grade

A new article from a group in the UK suggests that there is no difference in outcomes between patients with localized disease and with Gleason scores of 4 + 3 = 7 or 3 + 4 = 7 when their PSA is ≤ 10 and they are treated with iodine-125-based, permanent seed brachytherapy. … READ MORE …

Prostate cancer news reports: Wednesday, November 25, 2009

There have been a number of interesting reports over the past couple of days that are summarized briefly below. They encompass such topics as:

  • The validity of the Epstein criteria in predicting clinically indolent prostate cancer
  • MRI and MRSI in patient work-up prior to treatment for stage T1c disease
  • Contrast-enhanced, color Döppler ultrasound and prostate biopsy
  • Gleason scores and cancer “laterality” on biopsy and after surgery
  • Accuracy of prediction of “unilateral” prostate cancer, and implications for focal surgery
  • Patient age and probability of indolent disease
  • Testosterone levels, comorbidities, ADT, and mortality
  • A new “prostate mechanical imaging system” … READ MORE …